05 July 2022>: Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
Xenia Bacinschi 1E , Gabriel Cristian Popescu 2C , Anca Zgura 1C* , Laurentia Gales 1F , Anghel Rodica 1A , Adriana Mercan 3D , Dragos Serban 4D , Bogdan Haineala 5B , Letitia Toma 3C , Laura Iliescu 3FDOI: 10.12659/MSM.936706
Med Sci Monit 2022; 28:e936706
Table 1 Baseline characteristics of the study group.
Mean age | 62.1±24.8 years |
Sex ratio | Males: 194 (33.04%)Females: 263 (66.95%) |
Mean HCV RNA | 1 067 865±253.151 IU/mL |
F2 fibrosis | 83 patients among which |
F3 fibrosis | 185 patients among which |
F4 fibrosis | 315 patients among which |
HCV relapse after liver transplantation | 4 patients |
Mean ALT levels | 65.5±18.4 IU/mL |
Mean bilirubin levels | 1.2±0.4 mg/dL |
Mean hemoglobin | 12.7±2.8 g/dL |
HCV – hepatitis C virus; ALT – alanine aminotranspherase. |